
Keywords: brain volume, chronic migraine, frontal lobe, magnetic resonance imaging, migraine, remodeling, thalamus, visual processing system
Abstract
The pathophysiology of migraine is complex. Neuroimaging studies reveal functional and structural changes in the brains of migraine patients. We sought to explore regional volume differences in intracranial structures in patients with episodic and chronic migraine. Sixteen episodic migraine patients, 16 chronic migraine patients, and 24 normal controls were recruited and underwent 3.0 T MRI scanning. The volumes of 142 brain regions were calculated by an automatic volumetric algorithm and compared with clinical variables. Results demonstrated that the volumes of specific regions in the frontal and occipital lobes, and the right putamen, were increased and the volume of the fourth ventricle was decreased in the episodic migraine patients compared with controls. The volumes of the left basal forebrain, optic chiasm, and, the fourth ventricle were decreased in the chronic migraine patients, while the occipital cortex and the right putamen were larger. Compared to episodic migraine patiants, chronic migraine patients displayed larger left thalamus and smaller frontal regions. Correlation analysis showed that headache frequency was negatively correlated with the volume of the right frontal pole, right lateral orbital gyrus, and medial frontal lobes and positively correlated with the volume of the left thalamus. The sleep disturbance score was negatively correlated with the volume of the left basal forebrain. This suggests that migraine patients have structural changes in regions associated with pain processing and modulation, affective and cognitive processing, and visual perception. The remodeling of selective intracranial structures may be involved in migraine attacks. This study was approved by the Ethics Committee of Chinese PLA General Hospital (approval No. S2018-027-02) on May 31, 2018.
Introduction
Migraine is a common neurological disorder which can cause significant disability (GBD 2016 Neurology Collaborators, 2019). Episodic migraine (EM) refers to fewer than 15 headache days per month, while chronic migraine (CM) implies headache occurring ≥ 15 days per month for at least 3 months with migraine features on ≥ 8 days every month (No authors listed, 2018). About 3% of patients may transform from EM to CM within a year (Lipton et al., 2015; Scher et al., 2017; Borkum, 2018). The prevalence of CM was reported to be 0.6–1.7% in Asia-Pacific region (Stark et al., 2013) and 1–2% in the global population (Burch et al., 2019). A number of risk factors, such as increased headache frequency, acute medication overuse, and depression are related to the transition from EM to CM, termed “chronification” (Buse et al., 2019). CM associated with medication overuse, also called “medication overuse headache” (Goudarzi et al., 2016), returns to episodic form after medication withdrawal, and may not actually be CM (No authors listed, 2018).
The pathogenesis of migraine chronification has been only partially revealed. Neuroimaging studies of CM have found functional and microstructural alterations in the brainstem, hypothalamus, basal ganglia, and cortex, sites that are involved in pain processing. Some of the changes correlate with headache frequency and/or duration, while others may be associated with mood and emotion, cognitive dysfunction and insomnia (Coppola et al., 2017; Neeb et al., 2017; Schulte et al., 2017; Androulakis et al., 2018; Domínguezet al., 2019; Lee et al., 2019; Woldeamanuel et al., 2019). These functional and structural alterations reflect central plasticity of CM, but whether the changes were the etiology or the effects of migraine chronification has yet to be revealed. Neuroimaging findings were variable across different studies, probably due to the diversities of patients’ background, clinical aspects, imaging processing methods, and statistical power. Previous structural imaging studies have investigated alterations in gray matter volume or thickness (Coppola et al., 2017; Neeb et al., 2017; Woldeamanuel et al., 2019), iron deposition (Domínguez et al., 2019), white matter lesions (Zheng et al., 2014; Neeb et al., 2015) and textural features of gray matter (Chen et al., 2017). Among those morphometric studies, volumetric analysis was most widely performed, and may well reflect brain remodeling in migraine. We intended to assess for the intracranial volume changes in EM and CM by calculating the volume of 142 brain regions according to a commercial template (Neuromorphometrics, Somerville, MA, USA) using an automatic morphometric algorithm over the whole brain. Compared to previous volumetric studies that usually investigated the cortical voxelwise microstructural changes (Coppola et al., 2017; Neeb et al., 2017; Palm-Meinders et al., 2017), this study directly calculated the volume differences not only in the cortex, but also in the white matter and the ventricles in a more macroscopic view using the automatic morphometric algorithm.
This study investigated the global and regional brain volume changes in EM and CM patients compared with normal controls (NCs), the global and regional brain volume differences between EM and CM patients, and the correlation of altered brain-region volumes with headache duration, frequency, and intensity and the scores for anxiety, depression, cognition, and sleep quality in all migraine patients.
Subjects and Methods
Fifty-six subjects were included in this prospective cross-sectional study, comprising 16 EM patients, 16 CM patients and 24 NCs. Migraine patients were consecutively recruited from the Outpatient Headache Clinic of the Department of Neurology of the First Medical Center of Chinese PLA General Hospital. Diagnosis of EM and CM fulfilled the criteria of ICHD-3 (No authors listed, 2018) and only migraine patients without aura were included, aura being relatively uncommon in the Chinese population. Inclusion criteria were age 18–60 years old, right-handed, willing to engage in the study, and not taking prophylactic medication or acute headache medications for more than 10 days per month during the last 3 months. Patients with chronic somatic or psychiatric disorders such as hypertension, diabetes mellitus, hypercholesterolemia, cardiovascular diseases, brain trauma, neoplasm, infection, connective tissue diseases, other subtypes of headache, chronic somatic pain, severe anxiety or depression before the onset of headache, or substance addiction were also excluded Inclusion and exclusion criteria of NCs were similar to those of the patients, except for the diagnosis of migraine.
Demographic information and general headache data were collected. All the patients completed a Visual Analogue Scale (VAS) (Aicher et al., 2012) for pain and a Migraine Disability Assessment (MIDAS) questionnaire (Hung et al., 2006) for assessing the impact of headache. The ten-point VAS was structured with a score greater than 6 corresponding to severe pain, a score of 4–6 indicating moderate pain, and a score lower than 4 indicating mild pain. The MIDAS score is derived from five questions about missed time from work, household work, and missed days of nonwork activities. The higher the MIDAS score, the more severe the disability caused by migraine. Both patients and NCs underwent Hamilton Anxiety Scale (HAMA) (Matza et al., 2010, Nair et al., 2015), Hamilton Depression Scale (HAMD) (Zimmerman et al., 2013), Montreal Cognitive Assessment (MoCA) Beijing Version (www.mocatest.org), and General Sleep Disturbance Scale (GSDS) (Lee, 2007) assessment for evaluating anxiety, depression, cognition and sleep quality, respectively. A HAMA score 8–14 indicates mild anxiety; 15–23 indicates moderate anxiety; and ≥ 24 indicates severe anxiety (Matza et al., 2010). A HAMD score of 8–16 indicates mild depression; 17–23 indicates moderate depression; and ≥ 24 indicates severe depression (Zimmerman et al., 2013). The total score of MoCA is 30 and when the score falls below 26, cognitive impairment is present. The lower the MoCA score is, the worse the cognitive function. GSDS is a self-rated, 8-point scale arranged from 0 (never) to 7 (every day); and higher GSDS scores indicate more severely disturbed sleep (Lee, 2007). The above scales were evaluated by trained doctors. This study was approved by the Ethics Committee of Chinese PLA General Hospital (approval No. S2018-027-02) on May 31, 2018 (Additional file 1 (1.5MB, pdf) ). All the participants signed informed consents (Additional file 2 (4.7MB, tif) ) which complied with the Declaration of Helsinki before participating in the study. This study followed the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement (Additional file 3).
STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies
| Item No | Recommendation | Page No | |
|---|---|---|---|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 2 |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1-2 | ||
| Introduction | |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 2-3 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 3 |
| Methods | |||
| Study design | 4 | Present key elements of study design early in the paper | 1 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 3 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants | 3 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 3-4 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 4-5 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4-5 |
| Study size | 10 | Explain how the study size was arrived at | 5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 5 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 5 |
| (b) Describe any methods used to examine subgroups and interactions | NA | ||
| (c) Explain how missing data were addressed | |||
| (d) If applicable, describe analytical methods taking account of sampling strategy | 5 | ||
| (e) Describe any sensitivity analyses | |||
| Results | |||
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 6 |
| (b) Give reasons for non-participation at each stage | |||
| (c) Consider use of a flow diagram | 1 | ||
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 6 |
| (b) Indicate number of participants with missing data for each variable of interest | |||
| Outcome data | 15* | Report numbers of outcome events or summary measures | 7-10 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 7-10 |
| (b) Report category boundaries when continuous variables were categorized | NA | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA | ||
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | NA |
| Discussion | |||
| Key results | 18 | Summarise key results with reference to study objectives | 10 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 13 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 10- 13 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 13 |
| Other information | |||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 13 |
*Give information separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
MRI acquisition
Nicotine, alcohol, and caffeine were prohibited at least 12 hours prior to MRI scanning. For EM patients, MRI examinations were performed at least 3 days after the last migraine attack. Headache status was recorded for CM patients at MRI examination. All the MRI examinations were carried out on a GE 3.0 Tesla MRI scanner (DISCOVERY MR750, GE Healthcare, Milwaukee, WI, USA) with a conventional 8-channel quadrature head coil. High-resolution structural images were collected by a three-dimensional T1-weighted fast spoiled gradient recalled echo sequence with the parameters as follows: repetition time = 6.3 ms, echo time = 2.8 ms, flip angle = 15 degrees, field of view (Bilgiç, Kocaman et al., 2016) = 25.6 × 25.6 cm2, matrix size = 256 × 256, number of acquisition = 1180 contiguous axial slices, slice thickness = 1 mm. Subjects with obvious structural abnormalities and lesions in the brain, as assessed by a radiologist and neurologist, unless they were a few white matter lesions which may be related to migraine, were excluded from the study.
Data processing
All the MRI structural images were processed using computational Anatomy plugins (CAT, http://www.neuro.uni-jena.de/cat/) implemented within MATLAB 7.6 (The Mathworks, Natick, MA, USA) based on Statistical Parametric Mapping 12 (SPM 12, http://www.fil.ion.ucl.ac.uk/spm/). The volumes of 142 brain regions were automatically extracted from gray matter, white matter and cerebrospinal fluid according to the software as in our previous methods (Chen et al., 2018) composed of several procedures: spatial registration of individual brain images to an International Consortium for Brain Mapping (ICBM) space template (East Asian brains) (Mazziotta et al., 2001) to obtain normalized images, segmentation of normalized tissue into gray matter, white matter and cerebrospinal fluid, and volume extraction of 142 brain regions according to the Neuromorphometrics template.
Statistical analysis
The sample size was calculated by PASS 11 power analysis software (NCSS, Kaysville, UT, USA) based on our preliminary data with type 1 error rate of 0.5 and power of 90% in the one-way analysis of variance power analysis. Sample sizes of 14, 14, and 21 were obtained from the three groups whose means were to be compared. The total sample of 49 had 91% power to find means to be different among the groups using an F test with significance level of 0.05. The common standard deviation was assumed to be 0.21 in the means and 0.40 within a group.
Statistical analysis was performed with IBM SPSS 22.0 (IBM Corp., Armonk, NY, USA). The continuous data in demographics and clinical profiles were presented as the mean ± standard deviation. The differences in age, HAMA, HAMD, MoCA, sleep disturbance scale, total volume of gray matter, white matter, cerebrospinal fluid, and total intracranial volume were compared among the three groups using a one-way analysis of variance test followed by pairwise comparison using the Bonferroni method. Sex ratios of CM and EM were compared with the chi-squared test. Headache duration, headache frequency, VAS, number of doses of each medication per month, and MIDAS were compared between the EM and CM groups with an independent samples t-test. The differences in brain-region volume among EM, CM and NCs were calculated with a general linear model using age, sex and total intracranial volume as covariates followed by pairwise comparison corrected by the Bonferroni method. Partial correlation analyses were performed between the volumes of altered brain regions and the clinical parameters in EM and CM patients compared with controls for age, sex, and total intracranial volume. A value of P < 0.05 was considered statistically significant.
Results
Demographics and clinical data of EM, CM, and NCs
A total of 56 participants (16 EM patients, 16 CM patients and 24 NCs) were enrolled in this study. Only two patients in the CM group were headache-free during MRI scanning. Table 1 shows the demographics and clinical data. There were no statistical differences in age and sex among the three groups. Years with headache, headache intensity, and number of acute analgesics taken per month were not significantly different between EM and CM groups. Both EM and CM patients were significantly more anxious, depressed, and had worse sleep disturbance than NCs (P < 0.001). CM patients were more depressed and had more severe sleep disturbance than EM patients (P < 0.05). Cognitive function as measured by MoCA was much lower in CM patients than in EM patients and NCs (P = 0.001). CM patients endured a much higher burden of migraine disability than EM patients (P < 0.001).
Table 1.
Demographic and clinical information of EM patients, CM patients and NCs
| Item | EM patients (n=16) | CM patients (n=16) | NCs (n=24) | P-value |
|---|---|---|---|---|
| Age (yr) | 35.75±9.14 | 43.13±8.96 | 41.83±11.96 | 0.103 |
| Sex (female/male, n) | 3/13 | 3/13 | 5/19 | 0.981 |
| Headache duration (yr) | 13.38±8.09 | 11.25±9.30 | 0.496 | |
| Headache frequency (d/mon) | 3.66±2.82 | 25.06±5.87# | < 0.001 | |
| Headache side | 0.083 | |||
| Left | 4 | 0 | ||
| Right | 1 | 2 | ||
| Bilateral or middle | 5 | 10 | ||
| Left or right | 6 | 4 | ||
| VAS score | 8.31±1.48 | 7.88±1.45 | 0.408 | |
| Number of medications per month | 5.00±3.85 | 4.31±3.77 | 0.614 | |
| HAMA score | 15.25±10.41* | 21.63±10.98* | 2.39±1.47 | < 0.001 |
| HAMD score | 10.19±7.41* | 16.31±10.52*# | 1.13±1.06 | < 0.001 |
| GSDS score | 1.31±1.14* | 2.56±0.96*# | 0.13±0.34 | < 0.001 |
| MoCA score | 26.75±4.28 | 22.94±5.37*# | 28.13±2.07 | 0.001 |
| MIDAS score | 16.88±18.73 | 101.81±53.96# | < 0.001 |
Data are expressed as the mean ± SD, except sex and headache side. Sex and headache side were computed with the chi-square test. Headache frequency, VAS, the number of medications per month, and MIDAS were compared between EM and CM groups with independent samples t-test. The differences in age, HAMA, HAMD, GSDS, and MoCA among three groups were compared using one-way analysis of variance test followed by pairwise comparison using Bonferroni method. *P < 0.05, vs. NCs; #P < 0.05, vs. EM patients. CM: Chronic migraine; EM: episodic migraine; GSDS: General sleep disturbance scale; HAMA: Hamilton Anxiety Scale; HAMD: Hamilton Depression Scale; MIDAS: Migraine Disability Assessment questionnaire; MoCA: Montreal Cognitive Assessment; NCs: normal controls; VAS: Visual Analogue Scale.
Volume differences in intracranial structures among EM patients, CM patients and NCs
The total intracranial volume and total volume of gray matter, white matter, and cerebrospinal fluid yielded no statistical differences among EM patients, CM patients, and NCs (P > 0.05; Table 2). The results did not change after adjusted by age and using the Bonferroni correction for multiple group comparison.
Table 2.
Total intracranial volume (mL) of intracranial structure in EM patients, CM patients and NCs
| EM patients (n = 16) | CM patients (n = 16) | NCs (n = 24) | P-value | |
|---|---|---|---|---|
| Gray matter | 681.67±48.85 | 657.89±65.18 | 660.53±56.46 | 0.064 |
| White matter | 493.25±41.38 | 480.18±46.69 | 493.74±39.59 | 0.346 |
| Cerebrospinal fluid | 287.97±32.45 | 276.92±38.75 | 282.04±31.71 | 0.666 |
| Total intracranial volume | 1462.89±113.84 | 1414.99±144.17 | 1436.71±122.73 | 0.233 |
Data are expressed as the mean ± SD (one-way analysis of variance). CM: Chronic migraine; EM: episodic migraine; NCs: normal controls.
Region-volume analyses with multiple comparisons found significantly larger volumes of several regions in the frontal lobe, occipital lobe, right putamen and lower volume of the 4th ventricle of EM patients compared with NCs (P < 0.05; Table 3 and Figure 1).
Table 3.
Regional volume differences of brain regions among EM patients, CM patients and NCs
| Brain regions | CM patients (n = 16) | EM patients (n = 16) | NCs (n = 24) | P-value |
|---|---|---|---|---|
| R-putamen | 3.249±0.445↑ | 3.365±0.439↑ | 2.947±0.393 | 0.001 |
| R-frontal pole | 2.396±0.239▼ | 2.754±0.285↑ | 2.444±0.318 | 0.009 |
| R-lateral orbital gyrus | 1.941±0.228▼ | 2.263±0.287↑ | 1.921±0.259 | 0.005 |
| L-medial frontal cerebrum | 1.552±0.135▼ | 1.864±0.223↑ | 1.613±0.229 | 0.001 |
| R-medial frontal cerebrum | 2.001±0.209▼ | 2.354±0.309 | 2.143±0.262 | 0.012 |
| L-inferior frontal angular gyrus | 2.939±0.349 | 3.301±0.477↑ | 2.855±0.437 | 0.05 |
| R-inferior frontal angular gyrus | 3.222±0.311 | 3.641±0.404↑ | 3.202±0.375 | 0.012 |
| L-lingual gyrus | 6.902±0.553↑ | 6.901±0.776↑ | 6.342±0.567 | 0.001 |
| L-middle occipital gyrus | 5.424±0.570 | 6.059±0.499↑ | 5.363±0.660 | 0.012 |
| L-occipital fusiform gyrus | 3.232±0.420↑ | 3.209±0.240 | 3.017±0.338 | 0.03 |
| L-thalamus | 3.809±0.432▲ | 3.463±0.348 | 3.582±0.463 | 0.011 |
| L-4th ventricle | 0.094±0.014↓ | 0.100±0.022↓ | 0.112±0.019 | 0.004 |
| R-4th ventricle | 0.060±0.014↓ | 0.059±0.010↓ | 0.069±0.012 | 0.008 |
| Optic chiasm | 0.003±0.001↓ | 0.007±0.005 | 0.009±0.006 | 0.003 |
| L-basal forebrain | 0.633±0.059↓ | 0.694±0.052 | 0.692±0.060 | 0.003 |
Data are expressed as the mean ± SD (general linear model using age, sex and total intracranial volume as covariates followed by pairwise comparison corrected by Bonferroni method). Positive brain regions were presented at a threshold of P < 0.05. ↑: Volume larger than NCs; ↓: volume smaller than NCs; ▲: volume larger than EM; ▼: volume smaller than EM. CM: Chronic migraine; EM: episodic migraine; L: left; NCs: normal controls; R: right.
Figure 1.

Brain regions positive for volume alteration in episodic migraine compared with normal controls (P < 0.05, Bonferroni corrected).
(A–G) Orange color represents larger brain regions in the right frontal pole (P = 0.015), bilateral inferior frontal angular gyrus (P = 0.008), right lateral orbital gyrus (P = 0.004), left medial frontal cerebrum (P = 0.005), left lingual gyrus (P = 0.039), left middle occipital gyrus (P = 0.01) and right putamen (P = 0.013). (H) Blue color represents smaller brain regions in the 4th ventricle (P = 0.005).
Compared with NCs, greater volume was detected in the left lingual gyrus, left fusiform gyrus, and right putamen, while the optic chiasm, the 4th ventricle, and basal forebrain in CM patients (Table 3 and Figure 2) were lower in volume compared with NCs.
Figure 2.

Brain regions with volume alteration in chronic migraine compared with normal controls (P < 0.05, Bonferroni corrected).
(A–C) Orange color represents larger brain regions in left lingual gyrus (P = 0.001), left occipital fusiform gyrus (P = 0.034) and right putamen (P = 0.004). (D–F) Blue color represents smaller brain regions in left basal forebrain (P = 0.002), optic chiasm (P = 0.007) and the 4th ventricle (P = 0.002).
Compared with EM patients, the frontal lobe volume was smaller and the left thalamus volume was larger in CM patients (Table 3 and Figure 3).
Figure 3.
Brain regions positive for volume alteration in episodic migraine compared with chronic migraine (P < 0.05, Bonferroni corrected).
(A–C) Orange color represents larger regions in the right frontal pole (P = 0.021), right lateral orbital gyrus (P = 0.035), and bilateral medial frontal cerebrum (P = 0.002). (D) Blue color represents smaller brain regions in the left thalamus (P = 0.009).
Correlation of clinical parameters and the volume of different brain regions
Headache frequency (headache days per month) was negatively correlated with the volume of the right frontal pole (r = –0.571, P = 0.001), right lateral orbital gyrus (r = –0.395, P = 0.034), and left and right medial frontal lobes (r = –0.501, P = 0.006; r = –0.493, P = 0.007, respectively). Headache frequency was positively correlated with the volume of the left thalamus (r = 0.583, P = 0.001). The sleep disturbance scale was negatively correlated with the volume of the left basal forebrain (r = –0.410, P = 0.024; Figure 4). No significant correlation was found between other clinical parameters and the volume of brain regions.
Figure 4.

Correlation analysis of clinical profiles and the volume of positive brain regions.
(A) Headache frequency was positively correlated with the volume of the left thalamus (r = 0.583, P = 0.001) and negatively correlated with the right frontal pole (r = –0.571, P = 0.001), right lateral orbital gyrus (r = –0.395, P = 0.034), left medial frontal lobe (r = –0.501, P = 0.006) and right medial frontal lobe (r = –0.493, P = 0.007). (B) Sleep disturbance scale was negatively correlated with the volume of left basal forebrain (r = –0.410, P = 0.024). L: Left; R: right.
Discussion
This structural MRI study analyzed volume alterations of regions in the gray matter, the white matter, and the ventricles in migraine patients. In this study, the altered volume in several regions of prefrontal cortex, occipital lobe, right putamen, the 4th ventricle, the optic chiasm, and thalamus of migraine patients may indicate a central plasticity in migraine pathogenesis and chronification.
The prefrontal cortex has a key role in cognitive processing and pain modulation by wide connections with other brain areas, including the parietal cortex, insula, hippocampus, amygdala, thalamus, basal nuclei and periaqueductal gray matter (Ong et al., 2019). Previous studies have reported impaired prefrontal cortical function in migraine patients as shown by neuropsychological testing (Lev et al., 2010, 2013). Voxel-based morphometry studies generally demonstrated volume or density reduction of the frontal cortex in migraine patients (Kim et al., 2008; Schmitz et al., 2008; Valfrè et al., 2008; Jin et al., 2013; Coppola et al., 2017). Different from most voxel-based morphometry studies, EM patients in our study showed volume expansion of the frontal and occipital lobes. Those selected areas have been reported in previous studies to demonstrate volume alteration in migraine patients (Kim et al., 2008; Schmitz et al., 2008; Valfrè et al., 2008; Jin et al., 2013; Bilgiç et al., 2016; Yu et al., 2016; Coppola et al., 2017; Palm-Meinders et al., 2017). Therefore, we speculated that those regions indeed had alteration in EM patients.
Similar to our results, one study using whole-brain vertex-by-vertex analysis also found thickened prefrontal cortex in migraine patients without aura (Kim et al., 2014). More surface-based morphometry studies reported increased thickness in the somatosensory cortex (DaSilva et al., 2007) and motion-processing visual areas (Granziera et al., 2006) in EM patients. However, other surface-based morphometry studies reported thinner cortex in the frontal lobe, occipital lobe (Yu et al., 2016) and basal ganglia (Yuan et al., 2013) in migraine patients. The results from structural MRI studies are influenced by several factors, such as the patients’ ethnicity, migraine duration and/or frequency (Maleki et al., 2012), MRI parameters, morphometric methods, statistical efficacy, and ictal or interictal state (Coppola et al., 2015). In our study, those enlarged frontal areas in EM patients were no more larger in CM patients compared with NCs and the volume of some frontal regions was negatively correlated with headache frequency. The increased prefrontal cortex in EM patients may indicate adaptation of the central nervous system, which would enhance descending pain modulation at the stage of migraine attack. The volume decrease in prefrontal cortex in patients with higher headache frequency may reflect maladaptive volume reduction (Liu et al., 2017) and dysfunction of pain inhibition, which would facilitate migraine attacks and promote migraine chronification (Krummenacher et al., 2010; Bräscher et al., 2016). The mechanism of remodeling of migraine brain is unclear, but is considered to be related to the number and size of neuronal or glial cells and their synapses, and altered interstitial fluids or blood flow (May, 2011) probably resulting from neural excitability, neuroinflammation, vascular constriction or dilation, and neural degeneration.
Interestingly, our study detected decreased basal forebrain size in CM patients compared with NCs, which was not reported in previous structural MRI studies. The basal forebrain contains at least three distinct populations of neurons (cholinergic, glutamatergic, and GABAergic), which have extensive projections to cortical and subcortical areas to regulate arousal, motivation, and other behaviors (Agostinelli et al., 2019). An animal study found increased pain sensitivity after destruction of basal forebrain cholinergic neurons in rats, revealing that cholinergic transmission of basal forebrain may be involved in pain processing (Vierck et al., 2016). A quantitative electroencephalogram study found that migraine patients suffered from highly asymmetric values in anterior δ power and posterior α and θ waves, suggesting altered activity patterns in the cholinergic brainstem or basal forebrain nuclei and thalamocortical connections prior to migraine attack (Bjørk and Sand, 2008). Further, the basal forebrain is considered to play a role in regulating the sleep–wake cycle in animals (Hermanstyne et al., 2013). In our study, the volume of basal forebrain was negatively correlated with the sleep disturbance scale, which further supported that altered basal forebrain may be associated with poorer sleep in migraine patients.
The visual processing pathway is strongly associated with migraine pathophysiology and clinical manifestations (Marzoli and Criscuoli, 2017). Light stimulation is a possible trigger of migraine attack. Visual aura is the most frequent form of migraine aura. Photophobia is a common accompanying symptom of migraine. Light hypersensitivity in migraine has been considered to be associated with light transmission from the retina to the trigeminovascular thalamocortical pathway (Noseda et al., 2010). Several studies reported a thinner retinal nerve fiber layer (Reggio et al., 2017; Tak et al., 2018) and/or retinal ganglion cell layer (Reggio et al., 2017; Gunes et al., 2018) in migraine patients, and the thickness may be negatively correlated with headache frequency (Reggio et al., 2017). Our study demonstrated volume reduction of the optic chiasm in CM patients, which further supports the structural alteration of the visual processing pathway. Similar to a previous surface-based morphometry study which reported thickened motion-processing visual regions (MTt and V3A) in migraine patients (Granziera et al., 2006), our study found thickened occipital regions in EM and CM patients, indicating the remodeling of central visual system in migraine patients.
The deep gray matter basal ganglia are important in integrating sensory, motor, motivation, cognitive and procedural learning functions (Kreitzer and Malenka, 2008). Previous studies have found volume alteration, functional connectivity changes, and iron deposits (Kruit et al., 2009; Yuan et al., 2013; Rocca et al., 2014) in the basal ganglia of migraine patients. Similar to previous studies (Rocca et al., 2014; Neeb et al., 2017), our study demonstrated an enlarged right putamen in both EM and CM patients, supporting the role of the basal ganglia in migraine patients. Another essential deep gray matter structure in migraine is the thalamus, which is responsible for pain processing, sleep–wake cycle regulation, awareness, cognitive behaviors, and the modulation of visual information in migraine (Younis et al., 2019). The volume reduction of thalamic nuclei (Magon et al., 2015) or thalamic microstructural alteration (Granziera et al., 2014) in migraine has reported in previous studies. Our previous study found that the thalamic volume was increased in medication-overuse headache patients compared to NCs (Chen et al., 2017). In this study, neither EM nor CM patients showed volume difference from NCs in the thalamus, which was consistent with a previous study (Granziera et al., 2014). However, compared with EM patients, CM patients presented with thalamic enlargement on the left side (P = 0.004), and the volume was positively correlated with headache days per month, indicating the plasticity of the thalamus in migraine chronification.
The decreased volume of the 4th ventricle in EM and CM patients may reflect enlargement of the brainstem or cerebellum, although we did not find statistical differences in the size of those structures. The brainstem contains the ascending trigeminal pathway and descending pain modulatory system. The volume of brainstem conflicted with data from previous studies. Some studies showed that gray matter volume of the brainstem decreased in migraine patients (Marciszewski et al., 2018) and CM patients (Bilgiç et al., 2016). Others demonstrated larger brainstem and subnuclei in migraine with aura (Petrusic et al., 2019) and in medication-overuse headache (Chen et al., 2018). The volume of the cerebellum in migraine patients was generally decreased in several studies (Bilgiç et al., 2016; Demir et al., 2016; Messina et al., 2017).
Our study has some limitations. First, because most of the CM patients had headache on MRI scanning, it is not possible to exclude that the non-edematous volumetric alterations observed in CM patients might be influenced by the presence of headache (Coppola et al., 2015). Nevertheless, it is impossible to perform subgroup analysis according to patients with or without headache when taking MRI examinations, because the sample was too small to allow this. The sample was small since CM without medication overuse was less prevalent. Second, we only recruited migraine patients without aura. Whether the volume alteration in migraine with aura occurs in the same or different brain regions is unknown. Third, this was a cross-sectional study, and we could not prove that chronification caused volume alteration or that volume alteration caused chronification.
In conclusion, this study revealed regional volume changes in the brains of CM and EM patients. The volume alterations were mainly located in the frontal lobe, visual processing system, basal ganglia, and thalami, which are involved in pain modulation, affective/cognitive processing, visual processing and pain processing. The volume of some brain regions may dynamically change with different migraine frequencies. However, the underlying mechanism of the volume alteration needs further investigation.
Additional files
Additional file 1: (1.5MB, pdf) Hospital Ethics Approval.
Additional file 2 (4.7MB, tif) : Informed Consent Form.
Additional file 3: STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist.
Acknowledgments
We are very grateful to the colleagues in the headache center of Chinese PLA General Hospital for collecting patients’ data and the radiology department for MRI scanning.
Footnotes
Chinese Library Classification No. R445.2; R747.2; R321.81
Conflicts of interest: The authors declare that they have no conflicts of interest.
Financial support: This work was supported by the Natural Science Foundation of Hainan Province of China, No. 818MS153 (to ZYC); the National Natural Science Foundation of China, No. 81771200 (to ZD); the National Key Research and Development Projects of Beijing Science and Technology Plan of China, No. Z161100002616013 (to SYY); the Special Financial Grant from the China Postdoctoral Science Foundation, No. 2014T70960 (to ZYC); the Nursery Technology Innovation Fund of Chinese PLA General Hospital, No. 12KMM39 (to XYC). The funder had no role in the study design, data collection, anagement, analysis, and interpretation; paper writing; or decision to submit the manuscript for publication.
Institutional review board statement: The study was performed in strict accordance with the Declaration of Helsinki and relevant ethical requirement of the Ethics Committee of Chinese PLA General Hospital (approval No. S2018-027-02) on May 31, 2018.
Declaration of participant consent: The authors certify that they have obtained all appropriate participant consent forms from the conscious participants. In the forms, the participants have given their consent for their images and other clinical information to be reported in the journal. The participants understood that their names and initials will not be published.
Reporting statement: This study followed the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement.
Biostatistics statement: The statistical methods of this study were reviewed by the biostatistician of the medical school of Chinese PLA.
Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.
Data sharing statement: Datasets analyzed in the current study will be available from the corresponding author on reasonable request.
Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.
Funding: This work was supported by the Natural Science Foundation of Hainan Province of China, No. 818MS153 (to ZYC); the National Natural Science Foundation of China, No. 81771200 (to ZD); the National Key Research and Development Projects of Beijing Science and Technology Plan of China, No. Z161100002616013 (to SYY); the Special Financial Grant from the China Postdoctoral Science Foundation, No. 2014T70960 (to ZYC); the Nursery Technology Innovation Fund of Chinese PLA General Hospital, No. 12KMM39 (to XYC).
C-Editor: Zhao M; S-Editors: Yu J, Li CH; L-Editors: Cone L, Hindle A, Qiu Y, Song LP; T-Editor: Jia Y
References
- 1.Agostinelli LJ, Geerling JC, Scammell TE. Basal forebrain subcortical projections. Brain Struct Funct. 2019;224:1097–1117. doi: 10.1007/s00429-018-01820-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Aicher B, Peil H, Peil B, Diener HC. Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia. 2012;32:185–197. doi: 10.1177/03331024111430856. [DOI] [PubMed] [Google Scholar]
- 3.Androulakis XM, Krebs KA, Jenkins C, Maleki N, Finkel AG, Rorden C, Newman R. Central executive and default mode network intranet work functional connectivity patterns in chronic migraine. J Neurol Disord. 2018;6:393. doi: 10.4172/2329-6895.1000393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bilgiç B, Kocaman G, Arslan AB, Noyan H, Sherifov R, Alkan A, Asil T, Parman Y, Baykan B. Volumetric differences suggest involvement of cerebellum and brainstem in chronic migraine. Cephalalgia. 2016;36:301–308. doi: 10.1177/0333102415588328. [DOI] [PubMed] [Google Scholar]
- 5.Bjørk M, Sand T. Quantitative EEG power and asymmetry increase 36 h before a migraine attack. Cephalalgia. 2008;28:960–968. doi: 10.1111/j.1468-2982.2008.01638.x. [DOI] [PubMed] [Google Scholar]
- 6.Borkum JM. Harnessing migraines for neural regeneration. Neural Regen Res. 2018;13:609–615. doi: 10.4103/1673-5374.230275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Bräscher AK, Becker S, Hoeppli ME, Schweinhardt P. Different brain circuitries mediating controllable and uncontrollable pain. J Neurosci. 2016;36:5013–5025. doi: 10.1523/JNEUROSCI.1954-15.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631–649. doi: 10.1016/j.ncl.2019.06.001. [DOI] [PubMed] [Google Scholar]
- 9.Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache. 2019;59:306–338. doi: 10.1111/head.13459. [DOI] [PubMed] [Google Scholar]
- 10.Chen X, Chen Z, Dong Z, Liu M, Yu S. Morphometric changes over the whole brain in caffeine-containing combination-analgesic-overuse headache. Mol Pain. 2018a;14:1744806918778641. doi: 10.1177/1744806918778641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chen ZY, Chen XY, Liu MQ, Ma L, Yu SY. Volume gain of brainstem on medication-overuse headache using voxel-based morphometry. Chin Med J (Engl) 2018b;131:2158–2163. doi: 10.4103/0366-6999.240807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Chen Z, Chen X, Chen Z, Liu M, He H, Ma L, Yu S. Alteration of gray matter texture features over the whole brain in medication-overuse headache using a 3-dimentional texture analysis. J Headache Pain. 2017a;18:112. doi: 10.1186/s10194-017-0820-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Chen Z, Jia Z, Chen X, Liu M, Liu S, Ma L, Yu S. Volumetric abnormalities of thalamic subnuclei in medication-overuse headache. J Headache Pain. 2017b;18:82. doi: 10.1186/s10194-017-0791-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Coppola G, Di Renzo A, Tinelli E, Iacovelli E, Lepre C, Di Lorenzo C, Di Lorenzo G, Di Lenola D, Parisi V, Serrao M, Pauri F, Fiermonte G, Bianco F, Pierelli F. Evidence for brain morphometric changes during the migraine cycle: a magnetic resonance-based morphometry study. Cephalalgia. 2015;35:783–791. doi: 10.1177/0333102414559732. [DOI] [PubMed] [Google Scholar]
- 15.Coppola G, Petolicchio B, Di Renzo A, Tinelli E, Di Lorenzo C, Parisi V, Serrao M, Calistri V, Tardioli S, Cartocci G, Ambrosini A, Caramia F, Di Piero V, Pierelli F. Cerebral gray matter volume in patients with chronic migraine: correlations with clinical features. J Headache Pain. 2017;18:115. doi: 10.1186/s10194-017-0825-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.DaSilva AFM, Granziera C, Snyder J, Hadjikhani N. Thickening in the somatosensory cortex of patients with migraine. Neurology. 2007;69:1990–1995. doi: 10.1212/01.wnl.0000291618.32247.2d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Demir BT, Bayram NA, Ayturk Z, Erdamar H, Seven P, Calp A, Sazak M, Ceylan HG. Structural changes in the cerebrum, cerebellum and corpus callosum in migraine patients. Clin Invest Med. 2016;39:27495. [PubMed] [Google Scholar]
- 18.Domínguez C, López A, Ramos-Cabrer P, Vieites-Prado A, Pérez-Mato M, Villalba C, Sobrino T, Rodriguez-Osorio X, Campos F, Castillo J, Leira R. Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine. Neurology. 2019;92:e1076–e1085. doi: 10.1212/WNL.0000000000007047. [DOI] [PubMed] [Google Scholar]
- 19.GBD 2016 Neurology Collaborators. (2019) Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18:459–480. doi: 10.1016/S1474-4422(18)30499-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Goudarzi R, Zeraati H, Akbari Sari A, Rashidian A, Mohammad K. Population-based preference weights for the EQ-5D health states using the Visual Analogue Scale (VAS) in Iran. Iran Red Crescent Med J. 2016;18:e21584–e21584. doi: 10.5812/ircmj.21584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Granziera C, DaSilva AFM, Snyder J, Tuch DS, Hadjikhani N. Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med. 2006;3:e402. doi: 10.1371/journal.pmed.0030402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Granziera C, Daducci A, Romascano D, Roche A, Helms G, Krueger G, Hadjikhani N. Structural abnormalities in the thalamus of migraineurs with aura: a multiparametric study at 3 T. Hum Brain Mapp. 2014;35:1461–1468. doi: 10.1002/hbm.22266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Gunes A, Karadag AS, Yazgan S, Celik HU, Simsek A. Evaluation of retinal nerve fibre layer, ganglion cell layer and choroidal thickness with optical coherence tomography in migraine patients: a case-control study. Clin Exp Optom. 2018;101:109–115. doi: 10.1111/cxo.12585. [DOI] [PubMed] [Google Scholar]
- 24.Hermanstyne TO, Subedi K, Le WW, Hoffman GE, Meredith AL, Mong JA, Misonou H. Kv2.2: a novel molecular target to study the role of basal forebrain GABAergic neurons in the sleep-wake cycle. Sleep. 2013;36:1839–1848. doi: 10.5665/sleep.3212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Hung PH, Fuh JL, Wang SJ. The application of migraine disability assessment questionnaire (MIDAS) Acta Neurol Taiwan. 2006;15:43–48. [PubMed] [Google Scholar]
- 26.Jin C, Yuan K, Zhao L, Zhao L, Yu D, von Deneen KM, Zhang M, Qin W, Sun W, Tian J. Structural and functional abnormalities in migraine patients without aura. NMR Biomed. 2013;26:58–64. doi: 10.1002/nbm.2819. [DOI] [PubMed] [Google Scholar]
- 27.Kim JH, Kim JB, Suh SI, Seo WK, Oh K, Koh SB. Thickening of the somatosensory cortex in migraine without aura. Cephalalgia. 2014;34:1125–1133. doi: 10.1177/0333102414531155. [DOI] [PubMed] [Google Scholar]
- 28.Kim JH, Suh SI, Seol HY, Oh K, Seo WK, Yu SW, Park KW, Koh SB. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia. 2008;28:598–604. doi: 10.1111/j.1468-2982.2008.01550.x. [DOI] [PubMed] [Google Scholar]
- 29.Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron. 2008;60:543–554. doi: 10.1016/j.neuron.2008.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009;29:351–359. doi: 10.1111/j.1468-2982.2008.01723.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Krummenacher P, Candia V, Folkers G, Schedlowski M, Schönbächler G. Prefrontal cortex modulates placebo analgesia. Pain. 2010;148:368–374. doi: 10.1016/j.pain.2009.09.033. [DOI] [PubMed] [Google Scholar]
- 32.Lee MJ, Park BY, Cho S, Kim ST, Park H, Chung CS. Increased connectivity of pain matrix in chronic migraine: a resting-state functional MRI study. J Headache Pain. 2019;20:29. doi: 10.1186/s10194-019-0986-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lee SY. Validating the General Sleep Disturbance Scale among Chinese American parents with hospitalized infants. J Transcult Nurs. 2007;18:111–117. doi: 10.1177/1043659606298502. [DOI] [PubMed] [Google Scholar]
- 34.Lev R, Granovsky Y, Yarnitsky D. Orbitofrontal disinhibition of pain in migraine with aura: an interictal EEG-mapping study. Cephalalgia. 2010;30:910–918. doi: 10.1177/0333102409357249. [DOI] [PubMed] [Google Scholar]
- 35.Lev R, Granovsky Y, Yarnitsky D. Enhanced pain expectation in migraine: EEG-based evidence for impaired prefrontal function. Headache. 2013;53:1054–1070. doi: 10.1111/j.1526-4610.2012.02297.x. [DOI] [PubMed] [Google Scholar]
- 36.Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688–695. doi: 10.1212/WNL.0000000000001256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Liu HY, Chou KH, Lee PL, Fuh JL, Niddam DM, Lai KL, Hsiao FJ, Lin YY, Chen WT, Wang SJ, Lin CP. Hippocampus and amygdala volume in relation to migraine frequency and prognosis. Cephalalgia. 2017;37:1329–1336. doi: 10.1177/0333102416678624. [DOI] [PubMed] [Google Scholar]
- 38.Magon S, May A, Stankewitz A, Goadsby PJ, Tso AR, Ashina M, Amin FM, Seifert CL, Chakravarty MM, Müller J, Sprenger T. Morphological abnormalities of thalamic subnuclei in migraine: a multicenter MRI study at 3 Tesla. J Neurosci. 2015;35:13800–13806. doi: 10.1523/JNEUROSCI.2154-15.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Maleki N, Becerra L, Brawn J, Bigal M, Burstein R, Borsook D. Concurrent functional and structural cortical alterations in migraine. Cephalalgia. 2012;32:607–620. doi: 10.1177/0333102412445622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Marciszewski KK, Meylakh N, Di Pietro F, Macefield VG, Macey PM, Henderson LA. Altered brainstem anatomy in migraine. Cephalalgia. 2018;38:476–486. doi: 10.1177/0333102417694884. [DOI] [PubMed] [Google Scholar]
- 41.Marzoli SB, Criscuoli A. The role of visual system in migraine. Neurol Sci. 2017;38:99–102. doi: 10.1007/s10072-017-2890-0. [DOI] [PubMed] [Google Scholar]
- 42.Matza LS, Morlock R, Sexton C, Malley K, Feltner D. Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int J Methods Psychiatr Res. 2010;19:223–232. doi: 10.1002/mpr.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.May A. Experience-dependent structural plasticity in the adult human brain. Trends Cogn Sci. 2011;15:475–482. doi: 10.1016/j.tics.2011.08.002. [DOI] [PubMed] [Google Scholar]
- 44.Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, Woods R, Paus T, Simpson G, Pike B, Holmes C, Collins L, Thompson P, MacDonald D, Iacoboni M, Schormann T, Amunts K, Palomero-Gallagher N, Geyer S, Parsons L, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM) Philos Trans R Soc Lond B Biol Sci. 2001;356:1293–1322. doi: 10.1098/rstb.2001.0915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Messina R, Rocca MA, Colombo B, Teggi R, Falini A, Comi G, Filippi M. Structural brain abnormalities in patients with vestibular migraine. J Neurol. 2017;264:295–303. doi: 10.1007/s00415-016-8349-z. [DOI] [PubMed] [Google Scholar]
- 46.Nair AV, Shamsuddin K, John PS, Hämäläinen JA, Kurien MA. Correlation of visual analogue scale foot and ankle (VAS-FA) to AOFAS score in malleolar fractures using Indian language questionnare. Foot Ankle Surg. 2015;21:125–131. doi: 10.1016/j.fas.2014.10.006. [DOI] [PubMed] [Google Scholar]
- 47.Neeb L, Bastian K, Villringer K, Israel H, Reuter U, Fiebach JB. Structural gray matter alterations in chronic migraine: implications for a progressive disease. Headache. 2017;57:400–416. doi: 10.1111/head.13012. [DOI] [PubMed] [Google Scholar]
- 48.Neeb L, Bastian K, Villringer K, Gits HC, Israel H, Reuter U, Fiebach JB. No microstructural white matter alterations in chronic and episodic migraineurs: a case-control diffusion tensor magnetic resonance imaging study. Headache. 2015;55:241–251. doi: 10.1111/head.12496. [DOI] [PubMed] [Google Scholar]
- 49.No authors listed. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia. (3rd edition) 2018;38:1–211. doi: 10.1177/0333102417738202. [DOI] [PubMed] [Google Scholar]
- 50.Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, Digre K, Burstein R. A neural mechanism for exacerbation of headache by light. Nat Neurosci. 2010;13:239–245. doi: 10.1038/nn.2475. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Ong WY, Stohler CS, Herr DR. Role of the prefrontal cortex in pain processing. Mol Neurobiol. 2019;56:1137–1166. doi: 10.1007/s12035-018-1130-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Palm-Meinders IH, Arkink EB, Koppen H, Amlal S, Terwindt GM, Launer LJ, van Buchem MA, Ferrari MD, Kruit MC. Volumetric brain changes in migraineurs from the general population. Neurology. 2017;89:2066–2074. doi: 10.1212/WNL.0000000000004640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Petrusic I, Dakovic M, Zidverc-Trajkovic J. Volume alterations of brainstem subregions in migraine with aura. NeuroImage Clinical. 2019;22:101714. doi: 10.1016/j.nicl.2019.101714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Reggio E, Chisari CG, Ferrigno G, Patti F, Donzuso G, Sciacca G, Avitabile T, Faro S, Zappia M. Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. J Neurol. 2017;264:494–502. doi: 10.1007/s00415-016-8364-0. [DOI] [PubMed] [Google Scholar]
- 55.Rocca MA, Messina R, Colombo B, Falini A, Comi G, Filippi M. Structural brain MRI abnormalities in pediatric patients with migraine. J Neurol. 2014;261:350–357. doi: 10.1007/s00415-013-7201-y. [DOI] [PubMed] [Google Scholar]
- 56.Scher AI, Buse DC, Fanning KM, Kelly AM, Franznick DA, Adams AM, Lipton RB. Comorbid pain and migraine chronicity: The chronic migraine epidemiology and outcomes study. Neurology. 2017;89:461–468. doi: 10.1212/WNL.0000000000004177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Schmitz N, Arkink EB, Mulder M, Rubia K, Admiraal-Behloul F, Schoonman GG, Kruit MC, Ferrari MD, van Buchem MA. Frontal lobe structure and executive function in migraine patients. Neurosci Lett. 2008;440:92–96. doi: 10.1016/j.neulet.2008.05.033. [DOI] [PubMed] [Google Scholar]
- 58.Schulte LH, Allers A, May A. Hypothalamus as a mediator of chronic migraine: Evidence from high-resolution fMRI. Neurology. 2017;88:2011–2016. doi: 10.1212/WNL.0000000000003963. [DOI] [PubMed] [Google Scholar]
- 59.Stark RJ, Ravishankar K, Siow HC, Lee KS, Pepperle R, Wang SJ. Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review. Cephalalgia. 2013;33:266–283. doi: 10.1177/0333102412468677. [DOI] [PubMed] [Google Scholar]
- 60.Tak AZA, Sengul Y, Bilak Ş. Evaluation of white matter hyperintensities and retinal fiber layer, ganglion cell layer, inner-plexiform layer, and choroidal layer in migraine patients. Neurol Sci. 2018;39:489–496. doi: 10.1007/s10072-017-3234-9. [DOI] [PubMed] [Google Scholar]
- 61.Valfrè W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry reveals gray matter abnormalities in migraine. Headache. 2008;48:109–117. doi: 10.1111/j.1526-4610.2007.00723.x. [DOI] [PubMed] [Google Scholar]
- 62.Vierck CJ, Yezierski RP, Wiley RG. Pain sensitivity following loss of cholinergic basal forebrain (CBF) neurons in the rat. Neuroscience. 2016;319:23–34. doi: 10.1016/j.neuroscience.2016.01.038. [DOI] [PubMed] [Google Scholar]
- 63.Woldeamanuel YW, DeSouza DD, Sanjanwala BM, Cowan RP. Clinical features contributing to cortical thickness changes in chronic migraine - a pilot study. Headache. 2019;59:180–191. doi: 10.1111/head.13452. [DOI] [PubMed] [Google Scholar]
- 64.Younis S, Hougaard A, Noseda R, Ashina M. Current understanding of thalamic structure and function in migraine. Cephalalgia. 2019;39:1675–1682. doi: 10.1177/0333102418791595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Yu ZB, Peng J, Lv YB, Zhao M, Xie B, Liang ML, Li HT, Zhou ZH. Different mean thickness implicates involvement of the cortex in migraine. Medicine. 2016;95:e4824. doi: 10.1097/MD.0000000000004824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Yuan K, Zhao L, Cheng P, Yu D, Zhao L, Dong T, Xing L, Bi Y, Yang X, von Deneen KM, Liang F, Gong Q, Qin W, Tian J. Altered structure and resting-state functional connectivity of the basal ganglia in migraine patients without aura. J Pain. 2013;14:836–844. doi: 10.1016/j.jpain.2013.02.010. [DOI] [PubMed] [Google Scholar]
- 67.Zheng Z, Xiao Z, Shi X, Ding M, Di W, Qi W, Zhang A, Fang Y. White matter lesions in chronic migraine with medication overuse headache: a cross-sectional MRI study. J Neurol. 2014;261:784–790. doi: 10.1007/s00415-014-7267-1. [DOI] [PubMed] [Google Scholar]
- 68.Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013;150:384–388. doi: 10.1016/j.jad.2013.04.028. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.

